文献速递主动脉疾病

升主动脉疾病的胸主动脉腔内修复术:GREAT注册研究初步结果

Thoracic endovascular stent graft repair for ascending aortic diseases.
PubMed 文献 · J Vasc Surg · 2019-05-21

基于GREAT注册研究,2011年7月至2015年共5014例患者中仅6例(0.12%)因真正起源于升主动脉的疾病接受TEVAR。6例均获技术成功,无院内死亡、脑卒中、瓣膜损伤或心肌梗死,中位随访26个月无死亡、再干预或内漏等并发症。初步显示升主动脉TEVAR短期结果满意,但超适应症使用标准器械仍需长期随访验证。

要点

  • 升主动脉TEVAR在真实世界中选择性用于6例(0.12%)升主动脉疾病患者。
  • 短期主要临床成功率达100%,无TEVAR相关院内死亡及神经系统并发症。
  • 中位随访26个月无死亡、再干预或装置相关并发症,耐久性待更长随访确认。

核心结论

  • 升主动脉TEVAR的初步真实世界经验显示短期随访结果满意。
  • 虽存在标准器械超适应症使用的担忧,但未观察到TEVAR相关并发症。
  • 需更长随访数据确认结果的耐久性。

研究设计与样本

  • 基于全球腔内主动脉治疗注册研究(GREAT)的回顾性分析。
  • 2011年7月至2015年共纳入5014例患者,其中6例(0.12%)因真正起源于升主动脉的疾病接受TEVAR。
  • 排除zone 0近端锚定区但无升主动脉疾病者,以及既往开放或腔内修复的再干预病例。
  • 6例中男性3例、女性3例,平均年龄69岁±10岁(范围58-83岁)。

主要发现

  • TEVAR指征包括动脉粥样硬化性动脉瘤4例(其中破裂1例)、复杂性A型夹层1例(破裂)和假性动脉瘤1例。
  • 平均最大主动脉病变直径60 mm±14 mm(范围39-77 mm)。
  • 3例(50%)接受紧急干预。
  • 主要临床成功率为100%,无TEVAR相关院内死亡,无需开放转流。
  • 未发生脑血管意外、瓣膜损伤或心肌梗死,所有患者存活出院。

临床怎么用

  • 对于真正起源于升主动脉的病变,TEVAR可在高度选择的患者中作为超适应症选择,短期结果满意。
  • 需注意本研究样本量极小(6例),不能据此推广至常规临床实践。
  • 术后需长期影像随访以监测内漏、移位等装置相关并发症。

局限性

  • 样本量极小(仅6例),结果外推性有限。
  • 为注册研究回顾性分析,可能存在选择偏倚。
  • 随访时间相对较短(中位26个月),耐久性尚未确立。
  • 标准器械用于升主动脉属超适应症,缺乏专用器械数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). METHODS: We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12%) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a "zone 0" proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. RESULTS: Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50%) cases. Primary clinical success was 100%. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. CONCLUSIONS: Preliminary "real-world" experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for "off-label" use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Piffaretti G, Grassi V, Lomazzi C, et al. Thoracic endovascular stent graft repair for ascending aortic diseases. J Vasc Surg. 2019. PMID: 31126763. doi:10.1016/j.jvs.2019.01.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。